抗血栓药物患者区域麻醉:ESAIC/ESRA联合指南
该联合指南由欧洲麻醉与重症监护学会和欧洲区域麻醉学会制定,旨在为接受抗血小板或抗凝药物的患者提供区域麻醉时减少血肿风险的循证建议。
要点
- 椎管内及深部不可压迫外周神经阻滞前后需根据抗血栓药物类型、剂量、肾功能及穿刺创伤性遵守特定时间间隔。
- 浅表可压迫外周神经阻滞的低出血风险操作不适用上述时间间隔。
- 超声引导、药物组合及出血风险评分不改变时间间隔,特定药物监测和逆转可影响时间间隔。
核心结论
- 接受抗血小板或抗凝药物的患者行神经阻滞及导管置入/拔除时,必须考虑出血风险。
- 医疗团队需识别血肿风险并具备检测和管理能力。
研究设计与样本
- 系统文献检索评估七种药物比较和十种临床干预,结局为外周和椎管内血肿。
主要发现
- 临床研究数量和质量有限,证据确定性均为GRADE C。
- 57.5%的推荐达成强共识(>90%同意),42.5%达成共识(75-90%同意)。
关键数值与推荐
- 椎管内或高出血风险外周神经阻滞(深部、不可压迫)前后,抗血栓药物给药需遵守特定时间间隔。
- 时间间隔根据抗凝药物类型和剂量、肾功能及是否发生创伤性穿刺而变化。
- 药物监测可指导某些时间间隔,维生素K拮抗剂和达比加群的特定逆转可影响时间间隔。
- 超声引导、药物组合和出血风险评分不改变时间间隔。
- 低出血风险外周神经阻滞(浅表、可压迫)不适用这些时间间隔。
临床怎么用
- 术前评估应明确抗血栓药物类型、剂量、肾功能及穿刺创伤性,以确定阻滞前后时间间隔。
- 对高出血风险操作需严格遵循时间间隔,低风险浅表阻滞可不受限。
- 团队应具备检测和管理血肿的能力,并关注导管置入和拔除时的出血风险。
局限性
- 临床研究数量有限且质量不高,证据确定性均为GRADE C。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bleeding is a potential complication after neuraxial and peripheral nerve blocks. The risk is increased in patients on antiplatelet and anticoagulant drugs. This joint guideline from the European Society of Anaesthesiology and Intensive Care and the European Society of Regional Anaesthesia aims to provide an evidence-based set of recommendations and suggestions on how to reduce the risk of antithrombotic drug-induced haematoma formation related to the practice of regional anaesthesia and analgesia. DESIGN: A systematic literature search was performed, examining seven drug comparators and 10 types of clinical intervention with the outcome being peripheral and neuraxial haematoma. Grading of Recommendations, Assessment, Development and Evaluation (GRADE) was used for assessing the methodological quality of the included studies and for formulating recommendations. A Delphi process was used to prepare a clinical practice guideline. RESULTS: Clinical studies were limited in number and quality and the certainty of evidence was assessed to be GRADE C throughout. Forty clinical practice statements were formulated. Using the Delphi-process, strong consensus (>90% agreement) was achieved in 57.5% of recommendations and consensus (75 to 90% agreement) in 42.5%. DISCUSSION: Specific time intervals should be observed concerning the adminstration of antithrombotic drugs both prior to, and after, neuraxial procedures or those peripheral nerve blocks with higher bleeding risk (deep, noncompressible). These time intervals vary according to the type and dose of anticoagulant drugs, renal function and whether a traumatic puncture has occured. Drug measurements may be used to guide certain time intervals, whilst specific reversal for vitamin K antagonists and dabigatran may also influence these. Ultrasound guidance, drug combinations and bleeding risk scores do not modify the time intervals. In peripheral nerve blocks with low bleeding risk (superficial, compressible), these time intervals do not apply. CONCLUSION: In patients taking antiplatelet or anticoagulant medications, practitioners must consider the bleeding risk both before and after nerve blockade and during insertion or removal of a catheter. Healthcare teams managing such patients must be aware of the risk and be competent in detecting and managing any possible haematomas.
引用
- Kietaibl S, Ferrandis R, Godier A, et al. Regional anaesthesia in patients on antithrombotic drugs: Joint ESAIC/ESRA guidelines. Eur J Anaesthesiol. 2022. PMID: 34980845. doi:10.1097/EJA.0000000000001600
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。